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Abstract 
Cystic fibrosis related diabetes (CFRD) is a common complication of cystic fibrosis (CF) and can be 
present in over 50% of adults with the disease. CFRD is associated with poorer clinical outcomes 
including accelerated pulmonary function decline and excess morbidity. The management of CFRD is 
complex and differs from that of type 1 and type 2 diabetes mellitus such that clinicians responsible 
for the care of people with CFRD must work closely with colleagues across a number of different 
specialities and disciplines. This review aims to discuss why a multi-disciplinary approach is 
important and how it can be harnessed to optimise the care of people with CFRD. 
 
  
1 Introduction 
Cystic fibrosis related diabetes (CFRD) is a common complication of cystic fibrosis  (CF), first 
recognised in 1955 when Shwachman described glucose handling abnormalities in a young child with 
CF. 
1
 Despite not being associated with some of the classic macrovascular complications of Type 1 
(T1DM) and Type 2 (T2DM) diabetes, CFRD causes excess morbidity and mortality in people with 
CF and hence presents unique challenges for clinicians, patients and families alike.
2-4
 Given the 
complexities of CFRD, a multi-disciplinary team approach is paramount to optimise outcomes. This 
review highlights the unique nature of the disease and the need for an MDT approach to optimise care 
and outcomes in people with CF. 
2 Epidemiology 
Life expectancy in people with CF has improved by over 40 years since the first report of CFRD. 
1
With improving survival comes an array of co-morbidities as a result of the prolonged disease 
process. CFRD is one such complication that already affects over one-third of all adults with CF in 
the UK and since prevalence increases with age, half of those over 40 years of age have the diagnosis. 
5
 
6
 Guidelines now recommend screening from 10 years of age and as such diagnosis in the 10-16 age-
groups has increased by 25%.  
6-9
 In addition to age, risk factors for CFRD include female sex, 
pancreatic insufficiency and Class I-II mutations  
10,11
, with female sex and poor lung function 
identified as predictors of poorer outcomes in CFRD. 
3,12
 
3 Pathophysiology and Clinical implications 
People with CFRD die from progressive respiratory failure rather than the macrovascular 
complications seen in T1DM and T2DM. In the 1980s, Finkelstein et al reported significantly reduced 
survival in CFRD and also observed deterioration in clinical status for up to 24 months prior to the 
diagnosis of CFRD being made.  
13
 It is now well recognised that CFRD is associated with accelerated 
pulmonary function decline and subsequent excess morbidity and mortality. 
3,4,14-18
  
Accelerated pulmonary function decline is thought to be related to a combination of metabolic and 
mechanical changes leading to the introduction of the term ‘diabetic pulmonopathy’. 19,20 The precise 
mechanisms underlying diabetic pulmonopathy remain incompletely understood but are likely multi-
factorial. Firstly, diabetes is known to be associated with increased infection and non-CF subjects 
with impaired glucose handling at diabetic thresholds have been shown to have higher morbidity and 
mortality from pulmonary infection than those with normal blood glucose levels. 
21-23
. In normal 
health, glucose in the airway surface liquid (ASL) is tightly regulated at extremely low levels 
24
 but in 
disease airway glucose rises: increased ASL levels occur in both diabetes and chronic lung disease, 
24,25
 and this is also true in CF where those with CFRD have higher ASL glucose than their non-
diabetic comparators. 
26
 Increased ASL glucose may provide an additional substrate for bacteria and 
increase bacterial growth and/or infection 
27-30
 Most workers have used exhaled breath condensate to 
estimate ASL but the only study to date measuring sputum glucose directly in people with CF found 
the highest levels in subjects with normal glucose tolerance and the lowest in CFRD. 
17
 This may be 
explained by increased glucose consumption by florid bacteria in the lungs of people with CFRD or 
by differences in glucose kinetics in their mucus filled lungs however regardless it confirms that the 
dynamics of airway glucose control in CF are more complex than previously thought. 
31
 
Hyperglycaemia causes reduced lung interstitium elasticity such that the lungs become stiffer and 
harder to inflate resulting in a decrease in FEV1 and FVC: furthermore thickening of the alveolar 
epithelium and the pulmonary capillary basal lamina results in diminished diffusion across the 
alveolar/capillary membrane. These changes culminate in a greater rate of  age-related decline in lung 
function 
32,33
 in those with diabetes.  Additionally, changes similar to those in the diabetic kidney, 
although less marked. 
34
 also occur in the arterioles and capillaries of the lung. It seems likely that 
these changes, taken together, all contribute to diabetic pulmonopathy in CF. 
4 Screening and diagnosis 
The diagnosis of CFRD can be difficult to detect biochemically and clinically. The classical 
symptoms of ‘polyuria, polydipsia and poor weight gain’ seen in conventional diabetes occur in only 
one third of patients with CFRD 
35
 and subsequently, relying on symptoms to make the diagnosis  
would fail to recognize the vast majority of CFRD. Routine annual screening is therefore advocated 
from the age of 10 years by both the American Diabetic Association (ADA) and National Institute of 
Clinical Excellence (NICE) in the UK. 
8,36
. A lack of identifiable endocrine support has previously 
been identified as a barrier to optimising screening programmes, 
37
 and a combined collaborative 
approach to screening involving respiratory and endocrine teams has previously been found to 
improve screening rates. 
38
 Hence close co-operation and communication between respiratory and 
diabetic teams is required to facilitate effective screening programmes so that CFRD can be diagnosed 
at the earliest opportunity. 
In addition to annual screening, unexplained lung function decline, weight loss or increased 
exacerbation rate may all trigger CF MDTs to look for CFRD in more detail. Screening is also 
particularly important in people with CF who have received solid organ transplantation as post-
transplant diabetes mellitus is common and can be independently associated with increased infections 
and mortality. 
39
 
Several screening tests have been proposed for CFRD: 50g glucose challenge test, 75g OGTT, OGTT 
60-minute glucose level, continuous glucose monitoring (CGM), fasting plasma glucose, HbA1c, 
serial capillary blood glucose monitoring or any combination of the above. 
40
However, in the UK the 
recent NICE guidelines suggest OGTT or CGM as the preferred screening methods, where if OGTT is 
used the diagnosis is confirmed with CGM. 
8
  
5 Management 
Principles of an MDT approach 
Effective CFRD management relies on co-ordination of many specialist CF healthcare professionals 
including the doctor, diabetologist, nurses, physiotherapists, psychologists, pharmacists and dieticians. 
Prevention of cross-infection, a cornerstone of CF care, makes the management of CFRD by the 
conventional approach unfeasible. For example, unsegregated communal clinics and group 
educational sessions are not appropriate in CFRD due to the risk of cross-infection. Services must 
therefore be tailored in a more individualised bespoke manner. As a consequence many CF centres 
have now developed dedicated joint-care clinics for diabetes, or even in-house CFRD specialist 
nurses. The CF annual review; a comprehensive, individualised assessment of each patient’s health 
and treatment regimens, includes either a screen for CFRD or, in those already diagnosed, a thorough 
assessment of glycaemic control, treatment adherence and complications.  
The principles of management of CFRD also differ from that of T1DM and T2DM. Treatment of T1 
and T2DM is tailored towards the prevention of vascular complications and although microvascular 
complications are reported in CFRD, they occur late and are less frequent than in other forms of 
diabetes. 
41
 Instead, the management of CFRD aims to stabilise and improve lung function and 
nutritional status.  
Pharmacological treatment of CFRD 
Insulin deficiency is the primary defect of CFRD and insulin treatment is associated not only with 
improved nutritional status and lung function 
42-45
 but also reduced pulmonary exacerbations, a key 
determinant of morbidity and mortality in people with CF. 
46
 Hence all guidelines agree that insulin 
replacement is the only recommended therapy. 
7,8,40
  
Although the benefits of insulin are well established, there remains uncertainty as to when treatment 
should be initiated. Conventional diabetic thresholds on OGTT and HbA1c are validated for the long-
term outcomes of people with T1 and T2DM. In CF, the deleterious clinical effects associated with 
CFRD often manifest themselves before dysglycaemia reaches conventional thresholds for diabetes 
and hence earlier intervention has been advocated by some guidelines, particularly where early 
dysglycaemia is seen concurrently with nutritional and/or pulmonary decline. 
47
 A handful of small 
studies have explored this strategy and although positive results were reported by some, a systematic 
review found the overall evidence base remains poor. 
48
 Large prospective studies are under way and 
will provide more evidence in the coming years (“CF-IDEA Trial” clinicaltrials.gov: CT01100892 
and “The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients” 
clinicaltrials.gov: NCT02496780).  
Commonly used insulin regimes include a long-acting insulin monotherapy regime or a bolus-only 
regime using rapid acting insulin at mealtimes. Basal-bolus regimes can be reserved for those with 
fasting hyperglycaemia, a relatively late sequel. 
49
 There is little evidence to support one regime over 
another, and treatment should instead be tailored to the individual’s needs, taking their dysglycaemia 
into account but also considering treatment burden, lifestyle and psychological factors. Given the 
anabolic effects of insulin, insulin doses should be uptitrated to the maximum dose safely tolerated by 
each patient.  
The role of the CF Diabetes Specialist Nurse  
Education and training of the person with CFRD is important for successful management and is 
best provided by the specialist CF nurse who has an understanding of all aspects of the CF 
disease state, including that related to diabetes.  The nurse specialist plays a pivotal role in any 
disciplinary team, acting not only as a first point of access, but also by coordinating the input 
provided by other members of the CFRD MDT. Liaison with multidisciplinary teams both 
external and internal is important and part of the nurse’s role is to ensure that all stakeholders 
are aware of the differences and requirements of a patient with CFRD. Such advocacy includes 
providing support outside the hospital setting, for example visits within the community when 
required. 
More recently, advanced nurse practitioner roles in CFRD have been developed and include 
non-medical prescribing, instigation and titration of insulin, and nurse led CFRD clinics and 
ward rounds.  As part of this, ongoing monitoring of those with CFRD through the use of CGM 
has been developed, and a tri-partite approach in conjunction with the CF dietician and person 
with CF to devise a plan of care based on CGM feedback seems likely to become gold standard. 
Although there is little evidence for or against different care models for people with CFRD, 
lessons from other forms of diabetes suggest involving the person with CFRD in the MDT 
approach helps develop a more realistic and achievable CFRD care plan. 50 51 
The advent of flash glucose monitoring (FGM) may help people with CFRD better manage their 
diabetes. Whilst no trials of FGM in CFRD have been performed, the demographics of people 
with CF and experience managing chronic conditions mean many are likely suitable candidates 
for FGM. FGM can be used as a short term “troubleshooting” strategy or as a longer-term tool for 
improved overall glycaemic control. 52 While FGM enables self-management, liaison with the 
diabetic nurse over the practicalities of access and initiation of the technology is needed and, 
similarly to other forms of diabetes, revised education for patients/caregivers is often needed. 53 
The ability for sharing of measurements for remote review gives the potentials for healthcare 
professionals to reassure, advise or intervene in a more timely and patient centred manner.  
Nutritional recommendations – the CF Specialist Dietician 
Individually tailored dietetic advice based on an understanding of CFRD and also its interaction with 
other CF-related complications is essential to help meet the nutritional needs of the person with CF 
whilst optimising blood glucose control.  However, there are no randomised controlled trials dictating 
best practice for the dietary management of people with CFRD, including the use of a low glycaemic 
index diet which is currently under review.
54,55
  As such, recommendations for CFRD are based 
predominantly on observational data and clinical consensus guidelines. 
7,8,40,56
 
Exocrine pancreatic insufficiency is present in nearly all people with CFRD and pancreatic enzyme 
replacement therapy (PERT) is a cornerstone of treatment.  Specialist CF dietetic advice to adjust and 
optimise PERT is essential along with co-operation between nutrition and diabetic teams particularly 
in the formulation of enteral feeding, where unique insulin regimes are sometimes required.  
Since insulin deficiency in CFRD potentiates the catabolic state, dietary recommendations differ 
significantly from those of T1 and T2DM (Table 1), and increased calorific intake is necessary to 
meet the metabolic demands associated with CF. Type of carbohydrate intake is also important in 
CFRD 
57 
demanding detailed education around the main foods groups.  Complete restriction of simple 
sugars is often not appropriate due to the calorific requirements needed for people with CF to remain 
nutritionally replete.  Dietary advice is therefore carefully structured to ensure calorific needs are met, 
alongside guidance for macronutrients. 
Ongoing management of CFRD and nutritional status requires regular follow-up and assessment. 
Serial glucose monitoring, by conventional methods or modern “flash” monitoring can be used in 
conjunction with food and activity diaries to identify how specific foods or circumstances such as 
stress, illness, medications and time of day, affect individuals glycaemic control. This approach can 
empower individuals with CFRD to tailor their treatment according to lifestyle such that outcomes are 
optimised whilst disruption to life is minimised. 
 
 
Table 1: Comparison of dietary recommendation between CFRD and other types of diabetes. Adapted 
from ISPAD Clinical Practice Consensus Guidelines 2018 
40
 
  Type 1 & Type 2 Diabetes   CFRD 
    Calories ≤100% of normal calorific intake for 
age and gender. Often have to 
watch or restrict calories to 
prevent overweight 
 
Require >120% of normal calorific 
intake for age and gender to prevent 
underweight 
  
  Fat <35% of total energy 
 
40% of total energy 
    Total 
Carbohydrate 
40-60% total energy 
 
45-50% total energy 
  
  Fibre Encouraged  
 
Encouraged in nutritionally replete 
individuals, but in poorly nourished 
patients it may compromise energy 
intake 
  
  Protein 10-20% of total energy; not >1g per 
kg body weight 
 
200% of reference nutrient intake 
  
  Salt Low intake, <6g/day   Increased requirement 
 
Role of the CF pharmacist 
CF is a multisystem disease with a large treatment burden and adherence can be problematic, further 
complicated in those with CFRD. The specialist CF pharmacist plays a pivotal role in the MDT in 
regard to medicines management and supporting adherence. 
58,59
 Minimising treatment burden is key 
to improving adherence and pharmacists are well placed to identify barriers to improving adherence in 
diabetes.  
60,61
 The pharmacist also plays a role in vigilance and monitoring of drug-drug interactions. 
Whilst insulin is a relatively inert medication, other medications commonly used in CF can impact 
glycaemic control, eg corticosteroids and fluoroquinolones. 
62
 
Role of CF Physiotherapist 
CFRD is associated with increased bacterial colonisation as well as increased pulmonary exacerbation 
rate and optimisation of chest clearance is therefore vital. 
63,64
 Physiotherapists and exercise 
physiologists also play a role in collaborating with patients to provide individualised exercise 
programmes.  The International Society for Paediatric and Adolescent Diabetes (ISPAD) advise that 
people with CFRD should do at least 150 minutes of moderate aerobic exercise a week. 
49
 
Screening for complications 
Whilst macrovascular complications of CFRD are rare, microvascular complications are more 
common: neuropathy has been reported in up to 50% of people with CFRD, retinopathy in 
approximately 40% of those diagnosed with CFRD for > 10 years, and CFRD is associated with a 4-
fold increase in chronic kidney disease. 
41,65
 Annual screening for microvascular complications is 
therefore recommended although attendance rates for screening schemes e.g. annual retinopathy 
screening remain poor 
66
. Complications of CFRD are likely to increase in parallel with overall 
increased survival and robust screening programmes must therefore be integrated within the CF MDT.  
Psychological  
CFRD carries a considerable treatment burden, and requires patients to adapt their lifestyles to 
accommodate new and potentially daunting treatment regimes. It is of note that CFRD diagnoses 
typically occur between 18-21 years of age, 
67
 thereby occurring in parallel to a number of other life 
transitional and developmental stages, all of which pose their own challenges and the potential to 
exacerbate any CFRD specific psychosocial stressors as they navigate these new life experiences.  
It is logical that a diagnosis of CFRD could have repercussions for patients’ mental health; indeed 
meta-analyses of the prevalence of psychological distress in type 1 and 2 diabetes suggest that rates of 
comorbid depression and anxiety are notably higher. 
68,69
 In CF, psychological distress (anxiety and 
depression) is already elevated across child, adolescent and adult populations 
70
.  A number of 
psychosocial stressors are shared between type 1 and 2 diabetes with CFRD e.g. adjustment to 
disease, dietary management, body image, and needle anxiety etc.  It seems reasonable, therefore, to 
expect psychological distress is higher for those with a diagnosis of CFRD. 
Psychological interventions such as cognitive behavioural, psychodynamic and systemic therapies 
have been suggested to be effective across the wider diabetic literature in terms of improving 
glycaemic control whilst simultaneously reducing distress. 
71,72
  However they have yet to be 
specifically explored within the CFRD population and any intervention must take into consideration 
the multifactorial nature of managing such a complex chronic life limiting disease.  
Future perspectives 
The CF horizon is dominated by CFTR modulators, but how these treatments will impact on CFRD is 
unclear. There is some evidence from small studies that insulin secretion improves with the use of 
ivacaftor, a CFTR corrector, yet similar effects have not been observed for the ivacaftor/lumacaftor 
combination licensed for people with the more common F508D mutation. 
73
 
74,75
 Excitingly, an 
observational post-marketing follow up study of ivacaftor use in the UK and US found an 
approximately 30% reduced relative risk for CFRD in those using ivacaftor compared to matched 
controls, although it is not known whether this was a result of reduced incidence of new CFRD 
diagnoses or improvement in glucose handling in those with a previously diagnosed. 
76
 
As life expectancy increases in CF, macrovascular complication may become more prevalent. To date 
macrovascular complications related to atherosclerotic disease are exceedingly rare in CF, with only 
one case, to our knowledge, in the literature. 
77
 In a future setting where CFTR modulators may 
improve survival, nutrition and pulmonary status, CF MDTs may need to reconfigure dietary advice 
to mitigate cardiovascular complications. 
Although insulin is the mainstay of treatment for CFRD currently, a recent clinical trial of oral 
repaglinide reported similar efficacy and safety as subcutaneous insulin 
78
  and the use of non-insulin 
therapies warrants further exploration in the coming years. Incretin axis targeted therapies are now 
routinely used in the treatment of T2DM and interest in their use is growing in CF. Concerns that 
some agents may be associated with weight loss and/or pancreatitis have led to initial caution, 
however some of these fears have been assuaged. 
79
 Incretin axis abnormalities have been reported in 
people with CF and investigation of incretin targeted therapies are therefore warranted. 
80-82
 
 Summary 
Cystic fibrosis is a complex multi-system disease, and CFRD remains one of its most important co-
morbidities with deleterious nutritional and pulmonary outcomes if left untreated. Optimal 
management of CFRD relies on timely diagnosis, insulin initiation and vigilance for diabetic 
complications. Achieving best care relies on a co-ordinated, proactive approach from many different 
healthcare professionals across a number of specialities. Importantly, the MDT must include the 
patient themselves and treatment must be tailored to the individual in order to minimise treatment 
burden, maximise adherence and improve long-term outcomes. 
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